What causes type 1 diabetes? Lessons from animal models

APMIS

Volumn 119, Issue SUPPL. 132, 2011, Pages 1-19

  Buschard, Karsten ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CYCLOSPORIN; DIAZOXIDE; GLIADIN; GLUTAMATE DECARBOXYLASE; GLYCOLIPID; INSULIN; POTASSIUM CHANNEL STIMULATING AGENT; TIFENAZOXIDE;

ANIMAL MODEL; ANTIGENICITY; ARTICLE; AUTOIMMUNITY; CANCER RISK; CELLULAR IMMUNITY; DISEASE COURSE; EFFECTOR CELL; ENTERITIS; ENTEROVIRUS; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; GLUTEN FREE DIET; HUMAN; HYPOGLYCEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LOW DRUG DOSE; NATURAL KILLER T CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; THYMUS; UNSPECIFIED SIDE EFFECT; VIRUS PATHOGENESIS;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIET, GLUTEN-FREE; DISEASE MODELS, ANIMAL; ENTEROVIRUS INFECTIONS; GLIADIN; HUMANS; IMMUNOLOGIC FACTORS;

EID: 79957579302     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02765.x     Document Type: Article

References (170)

1. Buschard K. Diabetic animal models. Apmis 1996;104:609-14.
2. Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J. Genetic liability of type 1 diabetes and the onset age among 22, 650 young Finnish twin pairs: a nationwide follow-up study. Diabetes 2003;52:1052-5.
3. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965;14:619-33.
4. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2:1279-83.
5. Buschard K. Passive transfer of virus induced diabetes mellitus with spleen cells. Acta Pathol Microbiol Scand [C ] 1978;86:29-32.
6. Buschard K, Rygaard J, Lund E. The inability of a diabetogenic virus to induce diabetes mellitus in athymic (nude) mice. Acta Pathol Microbiol Scand C 1976;84:299-303.
7. Jansen FK, Thurneyssen O, Muntefering H. Virus induced diabetes and the immune system. II -- Evidence for an immune pathogenesis of the acute phase of diabetes. Biomedicine 1979;31:1-2.
8. Buschard K, Hastrup N, Rygaard J. Virus-induced diabetes mellitus in mice and the thymus-dependent immune system. Diabetologia 1983;24:42-6.
9. Jansen FK, Muntefering H, Schmidt WA. Virus induced diabetes and the immune system. I. Suggestion that appearance of diabetes depends on immune reactions. Diabetologia 1977;13:545-9.
10. Haynes MK, Huber SA, Craighead JE. Helper-inducer T-lymphocytes mediate diabetes in EMC-infected BALB/c ByJ mice. Diabetes 1987;36:877-81.
11. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes 1988;37:1574-82.
12. Lipton R, LaPorte RE, Becker DJ, Dorman JS, Orchard TJ, Atchison J, et al. Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks. Diabetes Care 1990;13:776-84.
13. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8.
14. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 2007;104:5115-20.
15. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001;345:1036-40.
16. Liu C, Noorchashm H, Sutter JA, Naji M, Prak EL, Boyer J, et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007;13:1295-8.
17. Roep BO, Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999;48:484-90.
18. Buschard K, Madsbad S, Rygaard J. Depressed suppressor cell activity in patients with newly diagnosed insulin-dependent diabetes mellitus. Clin Exp Immunol 1980;41:25-32.
19. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 2008;181:7350-5.
20. Long SA, Walker MR, Rieck M, James E, Kwok WW, Sanda S, et al. Functional islet-specific Treg can be generated from CD4+. Eur J Immunol 2009;39:612-20.
21. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986;232:1545-7.
22. Kagi D, Odermatt B, Seiler P, Zinkernagel RM, Mak TW, Hengartner H. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997;186:989-97.
23. Dudek NL, Thomas HE, Mariana L, Sutherland RM, Allison J, Estella E, et al. Cytotoxic T-cells from T-cell receptor transgenic NOD8.3 mice destroy beta-cells via the perforin and Fas pathways. Diabetes 2006;55:2412-8.
24. Buschard K, Diamant M, Bovin LE, Mansson JE, Fredman P, Bendtzen K. Sulphatide and its precursor galactosylceramide influence the production of cytokines in human mononuclear cells. Apmis 1996;104:938-44.
25. Roeske-Nielsen A, Fredman P, Mansson JE, Bendtzen K, Buschard K. Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells. Immunol Lett 2004;91:205-11.
26. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of Autoimmunity by Targeting a Distinct, Noninvariant CD1d-reactive T Cell Population Reactive to Sulfatide. J Exp Med 2004;199:947-57.
27. Buschard K, Hanspers K, Fredman P, Reich EP. Treatment with sulfatide or its precursor, galactosylceramide, prevents diabetes in NOD mice. Autoimmunity 2001;34:9-17.
28. Buschard K, Schloot NC, Kaas A, Bock T, Horn T, Fredman P, et al. Inhibition of insulin-specific autoreactive T-cells by sulphatide which is variably expressed in beta cells. Diabetologia 1999;42:1212-8.
29. Buschard K, Blomqvist M, Osterbye T, Fredman P. Involvement of sulfatide in beta cells and type 1 and type 2 diabetes. Diabetologia 2005;48:1957-62.
30. Sandler S, Buschard K, Bendtzen K. Effects of 1, 25-dihydroxyvitamin D3 and the analogues MC903 and KH1060 on interleukin-1 beta-induced inhibition of rat pancreatic islet beta-cell function in vitro. Immunol Lett 1994;41:73-7.
31. Mathieu C, Laureys J, Sobis H, Vandeputte M, Waer M, Bouillon R. 1, 25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes 1992;41:1491-5.
32. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1, 25 dihydroxyvitamin D3. Diabetologia 1994;37:552-8.
33. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-9.
34. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-20.
35. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care 2005;28:1068-76.
36. Yamada K, Moriyama H, Okumachi Y, Arai T, Kameno M, Kishi M, et al. Intravenous administration of proinsulin 1 or 2-expressing fiber-mutant recombinant adenovirus vector protects against the development of diabetes in NOD mice. Ann N Y Acad Sci 2008;1150:183-6.
37. Simone EA, Wegmann DR, Eisenbarth GS. Immunologic "vaccination" for the prevention of autoimmune diabetes (type 1A). Diabetes Care 1999;22(Suppl 2):B7-15.
38. Buschard K. The thymus-dependent immune system in the pathogenesis of type 1 (insulin-dependent) diabetes mellitus. Animal model and human studies. Dan Med Bull 1985;32:139-51.
39. Buschard K. The functional state of the beta cells in the pathogenesis of insulin-dependent diabetes mellitus. Autoimmunity 1991;10:65-9.
40. Hollander PH, Asplin CM, Kniaz D, Hansen JA, Palmer JP. Beta-cell dysfunction in nondiabetic HLA identical siblings of insulin-dependent diabetics. Diabetes 1982;31:149-53.
41. Pundziute-Lycka A, Persson LA, Cedermark G, Jansson-Roth A, Nilsson U, Westin V, et al. Diet, growth, and the risk for type 1 diabetes in childhood: a matched case-referent study. Diabetes Care 2004;27:2784-9.
42. Buschard K, Buch I, Molsted-Pedersen L, Hougaard P, Kuhl C. Increased incidence of true type I diabetes acquired during pregnancy. Br Med J (Clin Res Ed) 1987;294:275-9.
43. Bingley PJ, Mahon JL, Gale EA. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008;31:146-50.
44. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;47:1661-7.
45. Pedersen CR, Bock T, Hansen SV, Hansen MW, Buschard K. High juvenile body weight and low insulin levels as markers preceding early diabetes in the BB rat. Autoimmunity 1994;17:261-9.
46. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 2001;44:914-22.
47. Pedersen CR, Hagemann I, Bock T, Buschard K. Intermittent feeding and fasting reduces diabetes incidence in BB rats. Autoimmunity 1999;30:243-50.
48. Halberg N, Henriksen M, Soderhamn N, Stallknecht B, Ploug T, Schjerling P, et al. Effect of intermittent fasting and refeeding on insulin action in healthy men. J Appl Physiol 2005;99:2128-36.
49. Bock T, Pakkenberg B, Buschard K. Genetic background determines the size and structure of the endocrine pancreas. Diabetes 2005;54:133-7.
50. Bache I, Bock T, Volund A, Buschard K. Previous maternal abortion, longer gestation, and younger maternal age decrease the risk of type 1 diabetes among male offspring. Diabetes Care 1999;22:1063-5.
51. Locatelli M, Buzzetti R, Galgani A, Montemari AL, Khazrai M, Petrone A, et al. Length of gestation and gender are associated with HLA genotypes at risk for Type 1 diabetes (Italian DIABFIN 3). Diabet Med 2007;24:916-9.
52. Cardwell CR, Stene LC, Joner G, Cinek O, Svensson J, Goldacre MJ, et al. Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia 2008;51:726-35.
53. Gotfredsen CF, Buschard K, Frandsen EK. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985;28:933-5.
54. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 1993;341:927-8.
55. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
56. Bowman MA, Campbell L, Darrow BL, Ellis TM, Suresh A, Atkinson MA. Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 1996;45:205-8.
57. Vlahos WD, Seemayer TA, Yale JF. Diabetes prevention in BB rats by inhibition of endogenous insulin secretion. Metabolism 1991;40:825-9.
58. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996;45:1427-30.
59. Ortqvist E, Bjork E, Wallensteen M, Ludvigsson J, Aman J, Johansson C, et al. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004;27:2191-7.
60. Skak K, Gotfredsen CF, Lundsgaard D, Hansen JB, Sturis J, Markholst H. Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener. Diabetes 2004;53:1089-95.
61. Buschard K, Josefsen K, Horn T, Fredman P. Sulphatide and sulphatide antibodies in insulin-dependent diabetes mellitus. Lancet 1993;342:840.
62. Buschard K, Hoy M, Bokvist K, Olsen HL, Madsbad S, Fredman P, et al. Sulfatide controls insulin secretion by modulation of ATP-sensitive K(+)-channel activity and Ca(2+)-dependent exocytosis in rat pancreatic beta-cells. Diabetes 2002;51:2514-21.
63. Buschard K, Blomqvist M, Mansson JE, Fredman P, Juhl K, Gromada J. C16:0 sulfatide inhibits insulin secretion in rat beta-cells by reducing the sensitivity of KATP channels to ATP inhibition. Diabetes 2006;55:2826-34.
64. Buschard K, Brogren CH, Ropke C, Rygaard J. Antigen expression of the pancreatic beta-cells is dependent on their functional state, as shown by a specific, BB rat monoclonal autoantibody IC2. Apmis 1988;96:342-6.
65. Aaen K, Rygaard J, Josefsen K, Petersen H, Brogren CH, Horn T, et al. Dependence of antigen expression on functional state of beta-cells. Diabetes 1990;39:697-701.
66. Bjork E, Kampe O, Karlsson FA, Pipeleers DG, Andersson A, Hellerstrom C, et al. Glucose regulation of the autoantigen GAD65 in human pancreatic islets. J Clin Endocrinol Metab 1992;75:1574-6.
67. Bjork E, Kampe O, Grawe J, Hallberg A, Norheim I, Karlsson FA. Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity. Autoimmunity 1993;16:181-8.
68. Buschard K, Jorgensen M, Aaen K, Bock T, Josefsen K. Prevention of diabetes mellitus in BB rats by neonatal stimulation of beta cells. Lancet 1990;335:134-5.
69. Buschard K, Bock T, Pedersen CR, Hansen SV, Aaen K, Jorgensen M, et al. Neonatal treatment with beta-cell stimulatory agents reduces the incidence of diabetes in BB rats. Int J Exp Diabetes Res 2000;1:1-8.
70. Warram JH, Krolewski AS, Gottlieb MS, Kahn CR. Differences in risk of insulin-dependent diabetes in offspring of diabetic mothers and diabetic fathers. N Engl J Med 1984;311:149-52.
71. Ekblond A, Schou M, Buschard K. Cytotoxicity towards neonatal versus adult BB rat pancreatic islet cells. Autoimmunity 1995;20:93-8.
72. Hartoft-Nielsen ML, Rasmussen AK, Kaas A, Feldt-Rasmussen U, Buschard K. Neonatal stimulation of the thyroid gland with iodine or suppression during adolescence with triiodothyronine changes the prevalence of autoimmune thyroiditis in BB rats. Eur J Endocrinol 2004;151:375-82.
73. Koczwara K, Bonifacio E, Ziegler AG. Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes. Diabetes 2004;53:1-4.
74. Palmer JP, Helqvist S, Spinas GA, Molvig J, Mandrup-Poulsen T, Andersen HU, et al. Interaction of beta-cell activity and IL-1 concentration and exposure time in isolated rat islets of Langerhans. Diabetes 1989;38:1211-6.
75. Ekblond A, Schou M, Buschard K. Mononuclear cytotoxicity and proliferation towards glucose stimulated rodent pancreatic islet cells. Autoimmunity 1997;25:97-108.
76. Maedler K, Storling J, Sturis J, Zuellig RA, Spinas GA, Arkhammar PO, et al. Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004;53:1706-13.
77. Josefsen K, Buschard K, Sorensen LR, Wollike M, Ekman R, Birkenbach M. Glucose stimulation of pancreatic beta-cell lines induces expression and secretion of dynorphin. Endocrinology 1998;139:4329-36.
78. Josefsen K, Sorensen LR, Buschard K, Birkenbach M. Glucose induces early growth response gene (Egr-1) expression in pancreatic beta cells. Diabetologia 1999;42:195-203.
79. Pedersen CR, Josefsen K, Bock T, Hansen SV, Buschard K. Beta-cell expression of 65-kDa heat-shock protein mRNA is function- and age-dependent. Apmis 1992;100:765-71.
80. Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997;9:4-9.
81. Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-control investigation. EURODIAB Substudy 2 Study Group. Diabetologia 2000;43:47-53.
82. Rami B, Schneider U, Imhof A, Waldhor T, Schober E. Risk factors for type I diabetes mellitus in children in Austria. Eur J Pediatr 1999;158:362-6.
83. Strachan DP. Hay fever, hygiene, and household size. Bmj 1989;299:1259-60.
84. Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 2007;179:5126-36.
85. Porcelli SA, Modlin RL. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 1999;17:297-329.
86. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science 1997;277:339-45.
87. Zajonc DM, Elsliger MA, Teyton L, Wilson IA. Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat Immunol 2003;4:808-15.
88. Zajonc DM, Maricic I, Wu D, Halder R, Roy K, Wong CH, et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med 2005;202:1517-26.
89. Yoshimoto T, Bendelac A, Hu-Li J, Paul WE. Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc Natl Acad Sci U S A 1995;92:11931-4.
90. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 1996;26:2989-98.
91. van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, et al. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001;100:144-8.
92. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001;7:1052-6.
93. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001;7:1057-62.
94. Hussain S, Wagner M, Ly D, Delovitch TL. Role of regulatory invariant CD1d-restricted natural killer T-cells in protection against type 1 diabetes. Immunol Res 2005;31:177-88.
95. Duarte N, Stenstrom M, Campino S, Bergman ML, Lundholm M, Holmberg D, et al. Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J Immunol 2004;173:3112-8.
96. Lehuen A, Lantz O, Beaudoin L, Laloux V, Carnaud C, Bendelac A, et al. Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998;188:1831-9.
97. Shi FD, Flodstrom M, Balasa B, Kim SH, Van Gunst K, Strominger JL, et al. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci U S A 2001;98:6777-82.
98. Falcone M, Facciotti F, Ghidoli N, Monti P, Olivieri S, Zaccagnino L, et al. Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 2004;172:5908-16.
99. Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity 2002;17:725-36.
100. Novak J, Beaudoin L, Griseri T, Lehuen A. Inhibition of T cell differentiation into effectors by NKT cells requires cell contacts. J Immunol 2005;174:1954-61.
101. Ilyinskii PO, Wang R, Balk SP, Exley MA. CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo. J Virol 2006;80:7146-58.
102. Kondrashova A, Reunanen A, Romanov A, Karvonen A, Viskari H, Vesikari T, et al. A six-fold gradient in the incidence of type 1 diabetes at the eastern border of Finland. Ann Med 2005;37:67-72.
103. Gale EA. A missing link in the hygiene hypothesis? Diabetologia 2002;45:588-94.
104. Ljungberg M, Korpela R, Ilonen J, Ludvigsson J, Vaarala O. Probiotics for the prevention of beta cell autoimmunity in children at genetic risk of type 1 diabetes--the PRODIA study. Ann N Y Acad Sci 2006;1079:360-4.
105. Engkilde K, Buschard K, Hansen AK, Menne T, Johansen JD. Prevention of diabetes in NOD mice by repeated exposures to a contact allergen inducing a sub-clinical dermatitis. PLoS One 2010;5:e10591.
106. Arrenberg P, Halder R, Kumar V. Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. J Cell Physiol 2009;218:246-50.
107. Hoorfar J, Buschard K, Dagnaes-Hansen F. Prophylactic nutritional modification of the incidence of diabetes in autoimmune non-obese diabetic (NOD) mice. Br J Nutr 1993;69:597-607.
108. Funda DP, Kaas A, Bock T, Tlaskalova-Hogenova H, Buschard K. Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev 1999;15:323-7.
109. Funda DP, Kaas A, Tlaskalova-Hogenova H, Buschard K. Gluten-free but also gluten-enriched (gluten+) diet prevent diabetes in NOD mice; the gluten enigma in type 1 diabetes. Diabetes Metab Res Rev 2008;24:59-63.
110. Scott FW, Rowsell P, Wang GS, Burghardt K, Kolb H, Flohe S. Oral exposure to diabetes-promoting food or immunomodulators in neonates alters gut cytokines and diabetes. Diabetes 2002;51:73-8.
111. Schmid S, Koczwara K, Schwinghammer S, Lampasona V, Ziegler AG, Bonifacio E. Delayed exposure to wheat and barley proteins reduces diabetes incidence in non-obese diabetic mice. Clin Immunol 2004;111:108-18.
112. Maurano F, Mazzarella G, Luongo D, Stefanile R, D'Arienzo R, Rossi M, et al. Small intestinal enteropathy in non-obese diabetic mice fed a diet containing wheat. Diabetologia 2005;48:931-7.
113. Norris JM, Barriga K, Klingensmith G, Hoffman M, Eisenbarth GS, Erlich HA, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003;290:1713-20.
114. Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003;290:1721-8.
115. Scott FW, Rowsell P, Wang GS, Burghardt K, Kolb H, Flohe S. Oral exposure to diabetes-promoting food or immunomodulators in neonates alters gut cytokines and diabetes. Diabetes 2002;51:73-8.
116. Ejsing-Duun M, Josephsen J, Aasted B, Buschard K, Hansen AK. Dietary gluten reduces the number of intestinal regulatory T cells in mice. Scand J Immunol 2008;67:553-9.
117. Cosnes J, Cellier C, Viola S, Colombel JF, Michaud L, Sarles J, et al. Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol 2008;6:753-8.
118. Sblattero D, Maurano F, Mazzarella G, Rossi M, Auricchio S, Florian F, et al. Characterization of the anti-tissue transglutaminase antibody response in nonobese diabetic mice. J Immunol 2005;174:5830-6.
119. Malaisse WJ, Courtois P, Scott FW. Insulin-dependent diabetes and gut dysfunction: the BB rat model. Horm Metab Res 2004;36:585-94.
120. Neu J, Reverte CM, Mackey AD, Liboni K, Tuhacek-Tenace LM, Hatch M, et al. Changes in intestinal morphology and permeability in the biobreeding rat before the onset of type 1 diabetes. J Pediatr Gastroenterol Nutr 2005;40:589-95.
121. Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, et al. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 2006;49:2824-7.
122. Drago S, El Asmar R, Di Pietro M, Grazia Clemente M, Tripathi A, Sapone A, et al. Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006;41:408-19.
123. Jalonen T, Isolauri E, Heyman M, Crain-Denoyelle AM, Sillanaukee P, Koivula T. Increased beta-lactoglobulin absorption during rotavirus enteritis in infants: relationship to sugar permeability. Pediatr Res 1991;30:290-3.
124. Chirdo FG, Rumbo M, Anon MC, Fossati CA. Presence of high levels of non-degraded gliadin in breast milk from healthy mothers. Scand J Gastroenterol 1998;33:1186-92.
125. Jaakkola I, Jalkanen S, Hanninen A. Diabetogenic T cells are primed both in pancreatic and gut-associated lymph nodes in NOD mice. Eur J Immunol 2003;33:3255-64.
126. Chakir H, Lefebvre DE, Wang H, Caraher E, Scott FW. Wheat protein-induced proinflammatory T helper 1 bias in mesenteric lymph nodes of young diabetes-prone rats. Diabetologia 2005;48:1576-84.
127. Senger S, Luongo D, Maurano F, Mazzeo MF, Siciliano RA, Gianfrani C, et al. Intranasal administration of a recombinant alpha-gliadin down-regulates the immune response to wheat gliadin in DQ8 transgenic mice. Immunol Lett 2003;88:127-34.
128. Mueller DB, Koczwara K, Mueller AS, Pallauf J, Ziegler AG, Bonifacio E. Influence of early nutritional components on the development of murine autoimmune diabetes. Ann Nutr Metab 2009;54:208-17.
129. Pastore MR, Bazzigaluppi E, Belloni C, Arcovio C, Bonifacio E, Bosi E. Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab 2003;88:162-5.
130. Fuchtenbusch M, Ziegler AG, Hummel M. Elimination of dietary gluten and development of type 1 diabetes in high risk subjects. Rev Diabet Stud 2004;1:39-41.
131. Hansen AK, Ling F, Kaas A, Funda DP, Farlov H, Buschard K. Diabetes preventive gluten-free diet decreases the number of caecal bacteria in non-obese diabetic mice. Diabetes Metab Res Rev 2006;22:220-5.
132. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005;48:1565-75.
133. Buschard K, Pedersen C, Hansen SV, Hageman I, Aaen K, Bendtzen K. Anti-diabetogenic effect of fusidic acid in diabetes prone BB rats. Autoimmunity 1992;14:101-4.
134. Nicoletti F, Di Marco R, Morrone S, Zaccone P, Lembo D, Grasso S, et al. Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. Immunology 1994;81:317-21.
135. Brugman S, Klatter FA, Visser JT, Wildeboer-Veloo AC, Harmsen HJ, Rozing J, et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes?. Diabetologia 2006;49:2105-8.
136. Hageman I, Buschard K. Antidiabetogenic effect of fusidic acid in diabetes prone BB rats: a sex-dependent organ accumulation of the drug is seen. Pharmacol Toxicol 2002;91:123-8.
137. Kharagjitsingh AV, Prinsen K, Lemkes HH, de Vries RR, Roep BO, Buschard K. Reduced frequency of blood group Lewis a-b- in female Type 1 diabetes patients. Diabet Med 2008;25:236-8.
138. Cardwell CR, Stene LC, Joner G, Cinek O, Svensson J, Goldacre MJ, et al. Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia 2008;51:726-35.
139. Watts T, Berti I, Sapone A, Gerarduzzi T, Not T, Zielke R, et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci U S A 2005;102:2916-21.
140. Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 2006;55:1443-9.
141. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009;360:1646-54.
142. Hermann R, Knip M, Veijola R, Simell O, Laine AP, Akerblom HK, et al. Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes--indication of an increased environmental pressure? Diabetologia 2003;46:420-5.
143. Bache I, Bock T, Volund A, Buschard K. Previous maternal abortion, longer gestation, and younger maternal age decrease the risk of type 1 diabetes among male offspring. Diabetes Care 1999;22:1063-5.
144. Locatelli M, Buzzetti R, Galgani A, Montemari AL, Khazrai M, Petrone A, et al. Length of gestation and gender are associated with HLA genotypes at risk for Type 1 diabetes (Italian DIABFIN 3). Diabet Med 2007;24:916-9.
145. Cardwell CR, Stene LC, Joner G, Davis EA, Cinek O, Rosenbauer J, et al. Birthweight and the risk of childhood-onset type 1 diabetes: a meta-analysis of observational studies using individual patient data. Diabetologia 2010;53:641-51.
146. Cardwell CR, Stene LC, Joner G, Cinek O, Svensson J, Goldacre MJ, et al. Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia 2008;51:726-35.
147. Bock T, Svenstrup K, Pakkenberg B, Buschard K. Unbiased estimation of total beta-cell number and mean beta-cell volume in rodent pancreas. Apmis 1999;107:791-9.
148. Ylipaasto P, Klingel K, Lindberg AM, Otonkoski T, Kandolf R, Hovi T, et al. Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells. Diabetologia 2004;47:225-39.
149. Yin H, Berg AK, Tuvemo T, Frisk G. Enterovirus RNA is found in peripheral blood mononuclear cells in a majority of type 1 diabetic children at onset. Diabetes 2002;51:1964-71.
150. Andreoletti L, Hober D, Hober-Vandenberghe C, Fajardy I, Belaich S, Lambert V, et al. Coxsackie B virus infection and beta cell autoantibodies in newly diagnosed IDDM adult patients. Clin Diagn Virol 1998;9:125-33.
151. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 2009;52:1143-51.
152. Bonnevie-Nielsen V, Buschard K, Dyrberg T. Differential responsiveness to interferon-alpha in beta-cells and non-beta cells. Diabetes 1996;45:818-21.
153. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976;193:415-7.
154. Buschard K, Rygaard J. Is the diabetogenic effect of streptozotocin in part thymus-dependent? Acta Pathol Microbiol Scand C 1978;86:23-7.
155. Sorenson RL, Brelje TC. Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res 1997;29:301-7.
156. Pfleger C, Mortensen HB, Hansen L, Herder C, Roep BO, Hoey H, et al. Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 2008;57:929-37.
157. Kaas A, Pfleger C, Hansen L, Buschard K, Schloot NC, Roep BO, et al. Association of adiponectin, interleukin (IL)-1ra, inducible protein 10, IL-6 and number of islet autoantibodies with progression patterns of type 1 diabetes the first year after diagnosis. Clin Exp Immunol 2010;161:444-52.
158. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-26.
159. Wang ZJ, Zhang FM, Wang LS, Yao YW, Zhao Q, Gao X. Lipopolysaccharides can protect mesenchymal stem cells (MSCs) from oxidative stress-induced apoptosis and enhance proliferation of MSCs via Toll-like receptor(TLR)-4 and PI3K/Akt. Cell Biol Int 2009;33:665-74.
160. Josefsen K, Nielsen H, Lorentzen S, Damsbo P, Buschard K. Circulating monocytes are activated in newly diagnosed type 1 diabetes mellitus patients. Clin Exp Immunol 1994;98:489-93.
161. Oschilewski U, Kiesel U, Kolb H. Administration of silica prevents diabetes in BB-rats. Diabetes 1985;34:197-9.
162. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993;42:44-55.
163. Phillips JM, Parish NM, Bland C, Sawyer Y, De La Peña H, Cooke A. Type 1 Diabetes Development Requires Both CD4+ and CD8+ T cells and Can Be Reversed by Non-Depleting Antibodies Targeting Both T Cell Populations. Rev Diabet Stud 2009;6:97-103.
164. Buschard K, Madsbad S. A longitudinal study of virus antibodies in patients with newly diagnosed type 1 (insulin-dependent) diabetes mellitus. J Clin Lab Immunol 1984;13:65-70.
165. Palmer JP, Cooney MK, Ward RH, Hansen JA, Brodsky JB, Ray CG, et al. Reduced Coxsackie antibody titres in type 1 (insulin-dependent) diabetic patients presenting during an outbreak of Coxsackie B3 and B4 infection. Diabetologia 1982;22:426-9.
166. Huang X, Yuang J, Goddard A, Foulis A, James RF, Lernmark A, et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 1995;44:658-64.
167. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993;260:1942-6.
168. Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, et al. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol 2010;11:121-8.
169. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, et al. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care 2008;31:528-33.
170. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643-9.